Introduction
Colorectal cancer with ovarian metastasis (CRC-OM) is a relatively rare clinical manifestation characterized by a historically poor prognosis. Due to its rarity, standardized management protocols have been difficult to establish. This study analyzes over a decade of patient data from the Sun Yat-Sen University Cancer Center to determine the clinicopathological characteristics, prognostic indicators, and optimal treatment strategies for patients facing this diagnosis.
Methods
Researchers conducted a retrospective medical record review of 242 female patients diagnosed with CRC-OM between 2004 and 2017. The study focused on identifying how primary tumor location, histopathologic type, and surgical outcomes influenced overall survival. A critical metric evaluated was the success of cytoreductive surgery (CRS), categorized as "optimal" (complete or near-complete tumor removal) or "sub-optimal" (residual tumor remaining, R2). Statistical significance was determined using Hazard Ratios (HR) and 95% confidence intervals (CI).
Results and Key Findings
Patient Demographics and Disease Characteristics
The study cohort consisted of 242 female patients with a mean age of 45 years (range 16–74).
- Primary Site: The sigmoid colon was the most frequent primary location for the cancer (29.3%).
- Timing of Metastasis: 58.6% of patients presented with synchronous ovarian metastases at the time of their initial colorectal cancer diagnosis.
- Pathology: Mildly differentiated adenocarcinoma was the most common histopathologic type observed.
The Impact of Surgical Quality
Surgical intervention proved to be the most significant determinant of patient outcomes. Metastectomy was performed in 80.1% of patients.
- Optimal vs. Sub-optimal CRS: Patients who achieved optimal cytoreductive surgery saw a 5-year overall survival rate of 51.6%.
- Survival Gap: In contrast, those who underwent sub-optimal surgery (R2) had a 5-year survival rate of only 13.7% ($P < 0.01$).
Independent Prognostic Indicators
The analysis identified three primary factors that independently predicted overall survival:
- Metastectomy: The surgical removal of metastases was a strong protective factor (HR 0.03; 95% CI 0.222–0.008).
- Peritoneal Dissemination: Diffuse spread throughout the abdominal lining significantly worsened prognosis (HR 1.92; 95% CI 0.265–0.648).
- Chemotherapy Regimens: The use of multiple chemotherapy regimens was associated with improved survival (HR 0.49; 95% CI 0.301–0.82), suggesting that aggressive medical management alongside surgery is beneficial.
Discussion and Conclusion
The findings underscore that aggressive surgical intervention—specifically achieving optimal cytoreduction—is the cornerstone of effective CRC-OM management. The dramatic difference in 5-year survival rates (51.6% vs 13.7%) suggests that every effort should be made to reach the "optimal" surgical threshold. Furthermore, the benefit of multiple chemotherapy lines indicates that these patients may respond well to persistent systemic therapy.
While this study provides robust data from a high-volume center, its retrospective nature and single-center focus are limitations. Future prospective, multi-center trials are needed to further refine surgical techniques and validate these prognostic factors across broader populations. Nevertheless, for clinicians today, the data clearly supports a strategy of aggressive cytoreduction and comprehensive systemic treatment for patients with colorectal cancer and ovarian metastasis.
Summary updated